Ibsa Pharma INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$1.4Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
18,899clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $112K
2020 $163K
2021 $234K
2022 $234K
2023 $296K
2024 $247K
2025 $132K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Endocrinology, Diabetes & Metabolism $419K
Family Medicine $140K
Internal Medicine $134K
Family $125K
Physician Assistant $91K
Pain Medicine (Anesthesiology) $45K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Bruce Trippe Dothan, AL Endocrinology, Diabetes & Metabolism $16,251.30
Ernest Asamoah Indianapolis, IN Endocrinology, Diabetes & Metabolism $15,531.46
Todd Stitik Newark, NJ Pain Medicine (Physical Medicine & Rehabilitation) $15,234.46
Felice Gersh Irvine, CA Gynecology $12,483.32
Philip Doh Los Angeles, CA Pain Medicine (Anesthesiology) $10,743.36
Gerald Sacks Santa Monica, CA Pain Medicine (Anesthesiology) $10,544.79
Mae Sheikh Ali Jacksonville, FL Endocrinology, Diabetes & Metabolism $10,537.23
Eric Langer Sterling Heights, MI Endocrinology, Diabetes & Metabolism $9,953.77
Brittany Henderson Mount Pleasant, SC Endocrinology, Diabetes & Metabolism $9,573.67
Ammar Qoubaitary San Ramon, CA Endocrinology, Diabetes & Metabolism $8,868.30

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.